ISSN:
0730-2312
Keywords:
13-cis- retinoic acid
;
bladder carcinoma
;
chemoprevention
;
Life and Medical Sciences
;
Cell & Developmental Biology
Source:
Wiley InterScience Backfile Collection 1832-2000
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
Notes:
Animal studies indicate that 13-cis-retinoic acid (CRA) inhibits bladde tumor growth and is effedctive in treating patients with serious dermatologic disorders. A trial of CRA in patients at high risk for rec urrent, TA, T1 tumors was initiated at an experiemtnal dose o f0.5 mg/kg/d in three divided doeses, increasing to 1/mg/kg/d at foru weeks. Treatment of twenty eligible patients lasted for six months with an additional 24 month follow-up period. One patient was later excluded due to toxicity resulting in an early dose a reductionm.Eight patients stopped treatment before three months; of these five, had recurrences swithin three months, one developed pulmonary metastasis, and one developed a T2G3 tumore. Four patients stopped treatment between three and six months; three of them had rercurrences before one year and one had no evidence of disease years. Seven patients completed the course; of these three had recurrences within six months, and three more had recurrences at 8, 15, and 45 months, respectively.Toxicity was nearly universal; cheilosis, conjuctivitis, joint and eye pain, flashing lights, and erythrocyte sedimentation rate (ESR) over 60 were all noted. The lack of positive resutls and the frequency and severity of toxicity led to termination of the study. © 1992 Wiley-Liss, Inc.
Additional Material:
2 Tab.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1002/jcb.240501328
